3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
15
Gastrointestinal
9
Tumor-Agnostic
4
Genitourinary
4
Head & Neck
3
Gynecologic
3
Thoracic
1
Lymphoid
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Patient Participation
1
Melanoma
1
Interventions
pembrolizumab
326
Nivolumab
289
Ipilimumab
260
Cyclophosphamide
194
aldesleukin
145
Interleukin-2
109
fludarabine phosphate
107
Temozolomide
83
fludarabine
81
Dacarbazine
81
Radiotherapy
74
trametinib
73
Vemurafenib
69
dabrafenib
66
Biopsy
65
sargramostim
50
Bevacizumab
50
Radiosurgery
49
Paclitaxel
49
Peripheral Blood Stem Cell Transplantation
48
Magnetic Resonance Spectroscopy
48
Carboplatin
48
Imiquimod
47
Aminolevulinic Acid
47
binimetinib
45
Cisplatin
45
CTLA-4 Antigen
43
cemiplimab
42
Specimen Handling
42
atezolizumab
41
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Decision Support Techniques
×
Dermatologic
×
Clear all
NCT04240717
2022-11-07
PEF-Immun
University Hospital Heidelberg
Phase NA
Completed
126 enrolled